Trial Profile
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-Lowering Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Aegerion Pharmaceuticals
- 01 Feb 2023 Results assessing long-term hepatic safety of lomitapide from phase III clinical studies and extension study: NCT00730236, NCT00943306 and NCT02135705 published in the Liver International
- 01 Aug 2013 Lomitapide has been approved in Europe based on results from this trial according to an Aegerion Pharmaceuticals media release.
- 31 May 2013 The CHMP has adopted a positive opinion recommending marketing authorisation for lomitapide, according to an Aegerion Pharmaceuticals media release.